TWI857086B - 重構脂質體安那黴素之方法 - Google Patents

重構脂質體安那黴素之方法 Download PDF

Info

Publication number
TWI857086B
TWI857086B TW109121840A TW109121840A TWI857086B TW I857086 B TWI857086 B TW I857086B TW 109121840 A TW109121840 A TW 109121840A TW 109121840 A TW109121840 A TW 109121840A TW I857086 B TWI857086 B TW I857086B
Authority
TW
Taiwan
Prior art keywords
anamicin
liposomal
bag
saline
vial
Prior art date
Application number
TW109121840A
Other languages
English (en)
Chinese (zh)
Other versions
TW202114704A (zh
Inventor
唐諾 皮克
沃德瑪 普里貝
Original Assignee
唐諾 皮克
沃德瑪 普里貝
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 唐諾 皮克, 沃德瑪 普里貝 filed Critical 唐諾 皮克
Publication of TW202114704A publication Critical patent/TW202114704A/zh
Application granted granted Critical
Publication of TWI857086B publication Critical patent/TWI857086B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
TW109121840A 2019-06-28 2020-06-29 重構脂質體安那黴素之方法 TWI857086B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868190P 2019-06-28 2019-06-28
US62/868,190 2019-06-28

Publications (2)

Publication Number Publication Date
TW202114704A TW202114704A (zh) 2021-04-16
TWI857086B true TWI857086B (zh) 2024-10-01

Family

ID=74061076

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109121840A TWI857086B (zh) 2019-06-28 2020-06-29 重構脂質體安那黴素之方法
TW113132623A TW202500161A (zh) 2019-06-28 2020-06-29 脂質體安那黴素懸浮液

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113132623A TW202500161A (zh) 2019-06-28 2020-06-29 脂質體安那黴素懸浮液

Country Status (15)

Country Link
US (2) US12257262B2 (https=)
EP (1) EP3990041B1 (https=)
JP (1) JP7830131B2 (https=)
KR (1) KR20220027941A (https=)
CN (2) CN114728101B (https=)
AU (2) AU2020302784A1 (https=)
BR (1) BR112021026480A2 (https=)
CA (1) CA3144443A1 (https=)
ES (1) ES3049663T3 (https=)
IL (1) IL289433B1 (https=)
MX (1) MX2021015667A (https=)
PL (1) PL3990041T3 (https=)
SG (1) SG11202113005SA (https=)
TW (2) TWI857086B (https=)
WO (1) WO2020264161A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
EP4061810A4 (en) * 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US4863739A (en) 1987-05-19 1989-09-05 Board Of Regents, The University Of Texas System Liposome compositions of anthracycline derivatives
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
WO2001032145A1 (en) 1999-10-29 2001-05-10 Board Of Regents, The University Of Texas System Method of cancer treatment
TWI433693B (zh) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
ES2637072T3 (es) * 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
IL301603A (en) * 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
SI2768484T1 (sl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US8926994B2 (en) 2011-12-07 2015-01-06 The Methodist Hospital Research Institute Mesoporous silicon particles for the presentation of tumor antigens and adjuvant for anti-cancer immunity
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN107569508A (zh) * 2016-07-05 2018-01-12 江苏竞诺择生物医药科技有限公司 一种治疗造血系统增殖性疾病的药用组合物
KR20190067172A (ko) 2016-09-09 2019-06-14 아이리시스, 인크. 리포좀 항암 조성물
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
CN112955145A (zh) 2018-09-04 2021-06-11 密涅瓦神经科学有限公司 使用苯氧丙胺化合物治疗疼痛的方法
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
MX2021015668A (es) 2019-06-28 2022-04-18 Univ Texas Preparacion de un liofilizado de anamicina preliposomica.
EP4061810A4 (en) 2019-11-21 2023-12-20 Board of Regents, The University of Texas System Lung targeted anticancer therapies with liposomal annamycin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Perez-Soler, Roman, and TEXAS UNIV AT HOUSTON. "Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin." 1997).;期刊 Zou, Yiyu, et al. "Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity." Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995): 1369-1374. *
期刊 Zou, Yiyu, et al. "Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity." Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995): 1369-1374.

Also Published As

Publication number Publication date
KR20220027941A (ko) 2022-03-08
AU2024203593A1 (en) 2024-07-11
ES3049663T3 (en) 2025-12-17
AU2024203593B2 (en) 2025-08-14
EP3990041B1 (en) 2025-08-06
IL289433B1 (en) 2026-01-01
US11980634B2 (en) 2024-05-14
US20220105116A1 (en) 2022-04-07
CN114728101A (zh) 2022-07-08
CN114728101B (zh) 2023-07-14
SG11202113005SA (en) 2021-12-30
EP3990041A4 (en) 2023-07-12
WO2020264161A1 (en) 2020-12-30
TW202114704A (zh) 2021-04-16
TW202500161A (zh) 2025-01-01
MX2021015667A (es) 2022-04-18
US20240024345A1 (en) 2024-01-25
CA3144443A1 (en) 2020-12-30
PL3990041T3 (pl) 2026-02-23
CN116785242A (zh) 2023-09-22
JP2023523872A (ja) 2023-06-08
JP7830131B2 (ja) 2026-03-16
US12257262B2 (en) 2025-03-25
IL289433A (en) 2022-02-01
EP3990041A1 (en) 2022-05-04
BR112021026480A2 (pt) 2022-02-08
AU2020302784A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
US11980634B2 (en) Method of reconstituting liposomal annamycin
KR20050038011A (ko) 백금 응집체 및 이의 제조 방법
TWI872002B (zh) 安那黴素脂質體先質凍乾物之組成物
CN101091714A (zh) 含人参皂甙Rh2的前体脂质体及其制备方法
JP2006510674A (ja) 脂質：エモジン製剤に関する組成物および方法
JP2023523872A5 (https=)
CN102085189B (zh) 一种多西他赛长循环脂质体的制备方法
HK40073244A (en) Method of reconstituting liposomal annamycin
HK40073244B (en) Method of reconstituting liposomal annamycin
CN103830182A (zh) 一种长循环伊立替康脂质体组合物及其制备方法
CN100431525C (zh) 脂质体悬浮液制造方法及含该法所制脂质体悬浮液的产物
JPH02504027A (ja) プロスタグランジン‐脂質製剤
CN113304276A (zh) 用单唾液酸四己糖神经节苷脂修饰的脂质体及其制法和冻干应用